Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 193.86B |
| Revenue (ttm) | 46.87B |
| Net Income (ttm) | 10.82B |
| Shares Out | 1.98B |
| EPS (ttm) | 5.32 |
| PE Ratio | 18.45 |
| Forward PE | 13.06 |
| Dividend | 3.50 (3.62%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 6,871,839 |
| Average Volume | 3,895,607 |
| Open | 95.38 |
| Previous Close | 96.66 |
| Day's Range | 95.38 - 98.30 |
| 52-Week Range | 83.63 - 102.72 |
| Beta | 0.53 |
| RSI | 65.99 |
| Earnings Date | Jan 31, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis: Strong Execution With A P/E Discount
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why NVS stock is a Buy.
Key deals this week: Papa John's, Spirit Airlines, Novartis, Banco Santander and more
Novartis: Just What The Doctor Ordered
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return potential and a growing 3.5% dividend.
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
Novartis to buy Anthos Therapeutics for up to $3.1B
Novartis agrees to acquire Anthos for up to $3.1 bln
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company...
Novartis Super Bowl Ad Wasn’t Trying to be ‘Provocative.’ It’s About Action.
Novartis wanted viewer attention on Super Bowl night, and that's exactly what it got it. During Sunday's game, the first-time Big Game advertiser aired a 60-second Super Bowl commercial, "Your Attenti...
Pharma Makes its Mark on the Super Bowl—But Not Without Controversy
Most Super Bowl viewers expect to see ads for beer, snacks, and trucks. And Sunday's game delivered on all the usual commercial fronts. But in 2025, a somewhat more surprising trend emerged: pharmaceu...
Creatives React: A ‘Barrage of Boobs’ Steals Super Bowl in Novartis Ad
Does Novartis have your attention? In its first Super Bowl commercial, titled "Your Attention, Please," Novartis put a spotlight on breast cancer awareness with the help of Hailee Steinfeld, breast-ca...
Super Bowl Instant Replay: Hailee Steinfeld & Wanda Sykes Novartis Ad Is a Twist on Healthcare Promos
THE AD: In the Novartis 60-second Super Bowl ad, the first-time advertiser looks to bring attention to breast health with the help of breast cancer advocate Hailee Steinfeld, breast cancer survivor Wa...
Hailee Steinfeld Wants Your Attention in Novartis Super Bowl Ad
"Let's give breasts the attention they deserve most," Hailee Steinfeld initially declared in the Novartis Super Bowl ad teaser. Now, Steinfeld is back, along with cancer survivor Wanda Sykes, in Novar...
Novartis CEO Narasimhan looking for smaller deals to fill pipeline holes: WSJ
Novartis is considering further acquisitions to drive growth, CEO says
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.
Novartis AG 2024 Q4 - Results - Earnings Call Presentation
Novartis targets 5%+ annual sales growth through 2029 amid robust brand performance
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis delays Phase 3 readout for Ionis heart drug
Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read more here.
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
Novartis stock rose slightly early Friday after the company beat expectations. But the Street is closely watching for Entresto generics.
Novartis proposes dividend raise to CHF 3.50
Novartis (NVS) Surges on Strong Q4 Earnings and Robust Drug Sales
Novartis (NVS) Surges on Strong Q4 Earnings and Robust Drug Sales
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Novartis AG (NYSE: NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of $...